{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:56:19Z","timestamp":1787586979861,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>We assessed the efficacy and safety of PB compared with benzodiazepine (BZD)-based protocols in treating AWS in MICU.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Single-center, pre-post protocol implementation study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>The setting is a forty-bed MICU in a tertiary-level academic medical center.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS:<\/jats:title>\n            <jats:p>We included all patients admitted to the MICU with a primary diagnosis of AWS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>INTERVENTIONS:<\/jats:title>\n            <jats:p>Intravenous PB 260\u2009mg followed by 130-mg doses every 15\u201330 minutes as needed up to 15\u2009mg\/kg of ideal body weight versus escalating doses of BZD, to achieve a Clinical Institute Withdrawal Assessment Alcohol Scale-Revised score less than 10.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n            <jats:p>ICU and hospital length of stay (LOS), in addition to safety measures were the main outcomes of the study. A total of 102 patients were included, 51 in the PB arm and 51 in the BZD arm. There were no differences in baseline clinical characteristics. Half the patients in each group were admitted with delirium tremens. The use of PB-based protocol was associated with 35% reduction in median ICU LOS (1.5 d [interquartile range, 1.2\u20132.4 d] vs 2.3 d [1.4\u20134.8 d]; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.009) and 50% reduction in hospital LOS (3 d [2.7\u20134 d] vs 6 d [4\u201310 d]; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001). After adjustment for comorbidities and clinical factors, PB protocol decreased ICU LOS days by 40% (95% CI; 25.8\u201353.5%). PB group required fewer adjunctive medications to control symptoms (0.7 [0.5\u20131] vs 2.5 [2\u20133]; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001), less need for intubation (1\/51 [2%] vs 10\/10 [19.6%]; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.023) and less need for physical restraint (19\/51 [37.3%] vs 29\/51 [56.9%]; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.047), compared with the BZD group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>A protocol utilizing rapidly escalating doses of PB over a short period is an effective and safe alternative to BZD in treating AWS in MICU.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000898","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T16:13:53Z","timestamp":1681834433000},"page":"e0898","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Phenobarbital-Based Protocol for Alcohol Withdrawal Syndrome in a Medical ICU: Pre-Post Implementation Study"],"prefix":"10.1097","volume":"5","author":[{"given":"Mahmoud","family":"Alwakeel","sequence":"first","affiliation":[{"name":"Department of Pulmonary & Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Alayan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic Fairview Hospital, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Saleem","sequence":"additional","affiliation":[{"name":"Department of Pulmonary & Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saira","family":"Afzal","sequence":"additional","affiliation":[{"name":"Neurology Department, Cleveland Clinic Florida, Weston, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Immler","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cleveland Clinic Fairview Hospital, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Qualitative Health Sciences, Cleveland Clinic, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel","family":"Akbik","sequence":"additional","affiliation":[{"name":"Critical Care Department, Houston Methodist, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Duggal","sequence":"additional","affiliation":[{"name":"Department of Pulmonary & Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"key":"R1-20240807","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ane.12671","article-title":"Alcohol withdrawal syndrome: Mechanisms, manifestations, and management.","volume":"135","author":"Jesse","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"R2-20240807","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0025-7125(05)70554-X","article-title":"Pharmacotherapies for alcohol abuse. Withdrawal and treatment.","volume":"81","author":"Saitz","year":"1997","journal-title":"Med Clin North Am"},{"key":"R3-20240807","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/0885066605275353","article-title":"Management of delirium tremens.","volume":"20","author":"DeBellis","year":"2005","journal-title":"J Intensive Care Med"},{"key":"R4-20240807","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/oxfordjournals.alcalc.a008168","article-title":"Alcohol-related admissions to an inner city hospital intensive care unit.","volume":"31","author":"Marik","year":"1996","journal-title":"Alcohol Alcoholism"},{"key":"R5-20240807","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.amepre.2015.05.031","article-title":"2010 national and state costs of excessive alcohol consumption.","volume":"49","author":"Sacks","year":"2015","journal-title":"Am J Prev Med"},{"key":"R6-20240807","first-page":"118","article-title":"Alcohol withdrawal syndrome: Diagnostic and therapeutic methods.","volume":"53","author":"Attilia","year":"2018","journal-title":"Rivista di psichiatria"},{"key":"R7-20240807","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/cem.2019.421","article-title":"Benzodiazepine resistant alcohol withdrawal: What is the clinician\u2019s preferred definition?","volume":"22","author":"Langlois","year":"2020","journal-title":"CJEM"},{"key":"R8-20240807","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF03161171","article-title":"Resistant alcohol withdrawal: Does an unexpectedly large sedative requirement identify these patients early?","volume":"2","author":"Hack","year":"2006","journal-title":"J Med Toxicol"},{"key":"R9-20240807","first-page":"V03150234","article-title":"Behandling af benzodiazepinresistente alkoholabstinenssymptomer [Treatment of benzodiazepine-resistant alcohol withdrawal symptoms].","volume":"177","author":"Madsen","year":"2015","journal-title":"Ugeskr Laeger"},{"key":"R10-20240807","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0018578717720310","article-title":"Patient outcomes associated with phenobarbital use with or without benzodiazepines for alcohol withdrawal syndrome: A systematic review.","volume":"52","author":"Hammond","year":"2017","journal-title":"Hospital Pharmacy"},{"key":"R12-20240807","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/j.1552-4604.1982.tb02662.x","article-title":"Phenobarbital pharmacokinetics and bioavailability in adults.","volume":"22","author":"Nelson","year":"1982","journal-title":"J Clin Pharmacol"},{"key":"R13-20240807","first-page":"e13282","article-title":"Phenobarbital versus lorazepam for management of alcohol withdrawal syndrome: A retrospective cohort study.","volume":"13","author":"Hawa","year":"2021","journal-title":"Cureus"},{"key":"R14-20240807","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ajem.2019.01.053","article-title":"Single dose phenobarbital in addition to symptom-triggered lorazepam in alcohol withdrawal.","volume":"38","author":"Ibarra","year":"2020","journal-title":"Am J Emerg Med"},{"key":"R15-20240807","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajem.2019.01.002","article-title":"Benzodiazepines vs barbiturates for alcohol withdrawal: Analysis of 3 different treatment protocols.","volume":"37","author":"Nelson","year":"2019","journal-title":"Am J Emerg Med"},{"key":"R16-20240807","first-page":"1313","article-title":"Comparison of phenobarbital-adjunct versus benzodiazepine-only approach for alcohol withdrawal syndrome in the ED.","volume":"37","author":"Sullivan","year":"2019","journal-title":"Am J Emerg Med"},{"key":"R17-20240807","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/01.CCM.0000256841.28351.80","article-title":"A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens.","volume":"35","author":"Gold","year":"2007","journal-title":"Crit Care Med"},{"key":"R18-20240807","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.alcohol.2019.07.004","article-title":"Phenobarbital and symptom-triggered lorazepam versus lorazepam alone for severe alcohol withdrawal in the intensive care unit.","volume":"82","author":"Nguyen","year":"2020","journal-title":"Alcohol"},{"key":"R19-20240807","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1177\/0885066618783947","article-title":"The safety and utility of phenobarbital use for the treatment of severe alcohol withdrawal syndrome in the medical intensive care unit.","volume":"35","author":"Oks","year":"2020","journal-title":"J Intensive Care Med"},{"key":"R20-20240807","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4037\/ajcc2018745","article-title":"Treatment of alcohol withdrawal syndrome: phenobarbital vs CIWA-Ar protocol.","volume":"27","author":"Tidwell","year":"2018","journal-title":"American J Crit Care"},{"key":"R22-20240807","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/TA.0000000000000352","article-title":"Alcohol withdrawal syndrome in critically ill patients: Protocolized versus nonprotocolized management.","volume":"77","author":"Duby","year":"2014","journal-title":"J Trauma Acute Care Surg"},{"key":"R23-20240807","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/0018578720931464","article-title":"Evaluation of a phenobarbital-based protocol for severe alcohol withdrawal in critically ill patients.","volume":"56","author":"Goodberlet","year":"2021","journal-title":"Hosp Pharm"},{"key":"R24-20240807","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1513\/AnnalsATS.202102-121OC","article-title":"Implementation of a phenobarbital-based pathway for severe alcohol withdrawal: A mixed-method study.","volume":"18","author":"Bosch","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"R25-20240807","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ajem.2009.10.010","article-title":"A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal.","volume":"29","author":"Hendey","year":"2011","journal-title":"Am J Emerg Med"},{"key":"R26-20240807","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jemermed.2012.07.056","article-title":"Phenobarbital for acute alcohol withdrawal: A prospective randomized double-blind placebo-controlled study.","volume":"44","author":"Rosenson","year":"2013","journal-title":"J Emerg Med"},{"key":"R27-20240807","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13722-021-00226-w","article-title":"Should the CIWA-Ar be the standard monitoring strategy for alcohol withdrawal syndrome in the intensive care unit?","volume":"16","author":"Steel","year":"2021","journal-title":"Addict Sci Clin Pract"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000898","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T11:03:24Z","timestamp":1723028604000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000898","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}